What is it about?
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”. It presented the year-long study that followed the impact of once-daily MF/IND/GLY vs FLU/SAL or a placebo. Regardless of smoking history MF/IND/GLY in high and medium doses was preferred over FLU/SAL high does.
Featured Image
Photo by Mathew MacQuarrie on Unsplash
Why is it important?
Uncontrolled asthma is a common concern for smokers and non-smokers with decreased lung function. Understanding the impact of different options helps ensure patients have access to effective treatment.
Perspectives
Understanding the impact of smoking history on treatment is important to help support informed treatment.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) versus fluticasone/salmeterol (FLU/SAL) in ex-smoker and never smoker patients with inadequately controlled asthma: Post hoc analysis of IRIDIUM study, September 2021, European Respiratory Society (ERS),
DOI: 10.1183/13993003.congress-2021.pa3387.
You can read the full text:
Resources
Contributors
The following have contributed to this page
